The pharmaceutical landscape has been significantly reshaped with MSD (Merck & Co.) achieving a monumental victory: the US Food and…
Read More
Novartis Fabhalta Receives Traditional FDA Approval for IgAN Treatment
The U.S. Food and Drug Administration (FDA) has granted traditional approval to Novartis for Fabhalta (iptacopan), a groundbreaking oral Factor…
Read More
Kerendia Recommended for Broader Heart Failure Treatment in England, Offering New Hope for Patients with Preserved Ejection Fraction
England’s National Health Service (NHS) is set to expand its treatment options for chronic heart failure (CHF) with the National…
Read More
UK and Switzerland Forge Landmark Free Trade Agreement, Cementing Pharmaceutical Intellectual Property Protections
The United Kingdom and Switzerland have finalized a groundbreaking free trade agreement that explicitly enshrines intellectual property (IP) protections for…
Read More
J&J raises FY26 outlook following positive Q2 – Pharmaceutical Technology
Johnson & Johnson (J&J) announced robust second-quarter (Q2) revenues totaling approximately $25.3 billion, marking a significant 6.6% increase year-over-year (YoY).…
Read More
UK Life Sciences Sector Faces Funding Crisis Despite Government Prioritisation
The United Kingdom’s ambitious plans to foster growth within its vital life sciences sector are facing significant headwinds, with industry…
Read More
Paris is emerging as a focal point for Europe’s next phase in oncology, as science, capital, and industry converge at Campus Grand Parc.
The recent inauguration of THE HIVE at Campus Grand Parc in Paris marks a significant inflection point for Europe’s oncology…
Read More
Ipsen Acquires Rare Disease Specialist Memo Therapeutics for up to €700 Million, Bolstering Pipeline with Promising BK Polyomavirus Asset
Paris, France – In a significant strategic move to expand its rare disease portfolio, global biopharmaceutical company Ipsen announced today…
Read More
Bocunebart’s PACAP-Targeting Mechanism Positions it as a Potential First-in-Class Therapy in a Thin Pipeline of Novel Late-Stage Candidates
New Data Unveiled for Bocunebart, a Promising Migraine Preventive Targeting a Novel Pathway Munich, Germany – June 29, 2026 –…
Read More
Sanofi’s Nexviazyme Demonstrates Promising Results in Infants with Infantile-Onset Pompe Disease, Paving Way for Potential Label Expansion
Sanofi’s groundbreaking treatment for Pompe disease, Nexviazyme (avalglucosidase alfa), has achieved a significant milestone with the successful completion of the…
Read More
